| Ytd | 66.32% | |
| 1y | -84.81% |
| Open | 3.25 | Prev Close | 3.25 | Low | 3.15 | High | 3.30 | Mkt Cap | 1.42M |
| Vol | 5.22K | Avg Vol | 36.15K | EPS | -5.55 | P/E | -0.57 | Forward P/E | N/A |
| Beta | 0.94 | Short Ratio | N/A | Inst. Own | N/A | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 3.57 | 200-d Avg | 3.45 | 1yr Est | 0.00 |
NCEL News
Private Financing Reflects Strong Investor Confidence and Supports Advancement of Lead Type 1 Diabet
NewcelX Ltd. (("NewcelX", NASDAQ:NCEL), a clinical-stage regenerative medicine company devel
Laidlaw & Co. analyst Yale Jen initiates coverage on NewcelX (NASDAQ:NCEL) with a Buy rating
The appointment follows New c elX's recently announced successful FDA Type B Pre-IND meeting for NC
The FDA provided clarity regarding the regulatory pathway toward launching a clinical trial of NCEL-
FDA feedback supports NewcelX's planned development strategy for NCEL-101 in combination with Tegopr
Study published in Stem Cell Reports demonstrat e s that AstroRx ® - a therapy derived from NewcelX'
Pre-IND meeting has been scheduled with FDA to advance type 1 diabetes treatment to First-In-Human c
NewcelX submitted an FDA Pre-IND package for NCEL-101 to advance its type 1 diabetes treatment into
NewcelX and Eledon Pharmaceuticals are collaborating to advance one of the few scalable approaches t
NewcelX reports 2025 results, highlights NCEL-101 progress, $3.4 million financing potential, and pl
NewcelX Ltd. (NASDAQ:NCEL),– NewcelX Ltd. (NASDAQ:NCEL), a clinical-stage regenerative medicine comp
ZURICH, Switzerland, April 20, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (Nasdaq: NCEL),- NewcelX Ltd. (
Financing reflects strong investor confidence and supports advancement of lead Type 1 Diabetes progr
Collaboration Integrates Stem-Cell-Derived Islets with Targeted Immune Modulation ZURICH, Switzerlan
NLS Pharmaceutics Ltd. (NASDAQ: NCEL - Get Free Report) was the target of a significant growth in sh
Publication strengthens scientific positioning as Company progresses strategic discussions related t
Reinforces strategic focus on Type 1 Diabetes cell therapy and highlights expansion of Scientific Ad
ZURICH, Jan. 12, 2026 /PRNewswire/ -- NewcelX Ltd. (Nasdaq: NCEL) ("NewcelX" or the "Company"), a cl
4D Molecular Therapeutics (NASDAQ: FDMT - Get Free Report) and NLS Pharmaceutics (NASDAQ: NCEL - Get
ZURICH and NESS ZIONA, Israel, Jan. 5, 2026 /PRNewswire/ -- NewcelX Ltd. (NASDAQ: NCEL) ("NewcelX"),
USANA Health Sciences (NYSE: USNA - Get Free Report) and NLS Pharmaceutics (NASDAQ: NCEL - Get Free
Publication in key market advances NewcelX's global IP strategy across Asia and supports the Company
NLS Pharmaceutics (NASDAQ: NCEL - Get Free Report) and Akebia Therapeutics (NASDAQ: AKBA - Get Free
ZURICH and NESS ZIONA, Israel , Nov. 17, 2025 /PRNewswire/ -- NewcelX Ltd. (Nasdaq: NCEL) ("NewcelX"
